AnaptysBio (ANAB) has disclosed a new risk, in the Corporate Activity and Growth category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AnaptysBio may fail to realize the expected operational, financial, and strategic advantages from the proposed separation, and the combined market value of the two new public companies could be lower than the value of AnaptysBio’s stock absent the transaction. As smaller, less diversified entities, both companies could face heightened share-price volatility, execution challenges as independent issuers, and potential control and process weaknesses during and after the transition.
Overall, Wall Street has a Strong Buy consensus rating on ANAB stock based on 8 Buys.
To learn more about AnaptysBio’s risk factors, click here.